{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T12:23:15Z","timestamp":1777724595990,"version":"3.51.4"},"reference-count":38,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Bilecik Seyh Edebali University, Scientific Research Projects","award":["Project number: 2018-02.BSE\u00dc.01-01"],"award-info":[{"award-number":["Project number: 2018-02.BSE\u00dc.01-01"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Medicine"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:p>Combined administration of two or more drugs is emerging as a new strategy in triple-negative breast neoplasms. This is the first study to investigate the combination of the histone deacetylase inhibitor mocetinostat and the antimetabolite drug capecitabine in triple-negative mammary neoplasms in a preclinical mouse model. Thirty-five female mice were grouped into the control group, capecitabine group, mocetinostat group, and combined drugs group. At the end of the experimental period, body weight, and tumor weight were measured and tumor tissue and lung tissue were histologically examined. The results showed that the body weight of mice in the drug-treated groups was reduced by about 18%. Tumor weights were also reduced by 21% in the mocetinostat group, 27.5% in the capecitabine group, and 45% in the combined group. The combination of mocetinostat and capecitabine decreased the formation of tumors and metastases in lung tissue. In summary, the combination of mocetinostat and capecitabine was more effective than either drug alone in reducing the size of triple-negative breast neoplasms in a mouse model.<\/jats:p>","DOI":"10.1177\/10815589241309603","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:52:12Z","timestamp":1734483132000},"page":"320-327","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Investigation of the synergic effect of mocetinostat and capecitabine in a triple-negative breast neoplasms mouse model"],"prefix":"10.1177","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2490-9473","authenticated-orcid":false,"given":"Hacer","family":"Kaya \u00c7akir","sequence":"first","affiliation":[{"name":"Department of Molecular Biology and Genetics, Faculty of Science, Bilecik Seyh Edebali University, Bilecik, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onur","family":"Ero\u011flu","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology and Genetics, Faculty of Science, Bilecik Seyh Edebali University, Bilecik, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,1,14]]},"reference":[{"issue":"1","key":"e_1_3_3_2_2","first-page":"19","article-title":"Animal models of cancer: a review","volume":"4","author":"Navale A.","year":"2013","unstructured":"Navale A. Animal models of cancer: a review. Int J Pharm Sci Res 2013; 4(1): 19\u201328.","journal-title":"Int J Pharm Sci Res"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S302565"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000498"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24593"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.4147"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1177\/1758834014530023"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14698"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2011.577737"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.02.024"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914609"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2128"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2022.06.009"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6802"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2015.1095400"},{"issue":"3","key":"e_1_3_3_16_2","first-page":"695","article-title":"Preferential inhibition of bone metastases by 5\u2032-deoxy-5-fluorouridine and capecitabine in the 4T1\/luc mouse breast cancer model","volume":"14","author":"Hiraga T","year":"2005","unstructured":"Hiraga T, Hata K, Ikeda F, et al. Preferential inhibition of bone metastases by 5\u2032-deoxy-5-fluorouridine and capecitabine in the 4T1\/luc mouse breast cancer model. Oncol Rep 2005; 14(3): 695\u2013699.","journal-title":"Oncol Rep"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-1947"},{"issue":"11","key":"e_1_3_3_18_2","first-page":"1515","article-title":"In vitro anti-proliferative effect of capecitabine (Xeloda) combined with mocetinostat (MGCD0103) in 4T1 breast cancer cell line by immunoblotting","volume":"24","author":"Kaya \u00c7akir H","year":"2021","unstructured":"Kaya \u00c7akir H, Eroglu O. In vitro anti-proliferative effect of capecitabine (Xeloda) combined with mocetinostat (MGCD0103) in 4T1 breast cancer cell line by immunoblotting. Iran J Basic Med Sci 2021; 24(11): 1515\u20131522.","journal-title":"Iran J Basic Med Sci"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0188859"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.5455\/jice.20140123040224"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2021.109434"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.2174\/2211738507666190122111224"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2016.05.055"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.12.128"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.24272\/j.issn.2095-8137.2020.095"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.3816\/CBC.2004.s.005"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-07-2026"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4427"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70265-0"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.194"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.7150\/jca.34091"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201404396"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp359"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2011-4256"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-005-0079-3"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.12772"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0361"},{"key":"e_1_3_3_38_2","first-page":"6","article-title":"A non-toxic approach for treatment of breast cancer and its metastases: capecitabine enhanced photodynamic therapy in a murine breast tumor model","volume":"5","author":"Anand S","year":"2019","unstructured":"Anand S, Yasinchak A, Bullock T, et al. A non-toxic approach for treatment of breast cancer and its metastases: capecitabine enhanced photodynamic therapy in a murine breast tumor model. J Cancer Metastasis Treat 2019; 5: 6.","journal-title":"J Cancer Metastasis Treat"},{"issue":"6","key":"e_1_3_3_39_2","first-page":"905","article-title":"Decoction plus or minus formula combined with capecitabine inhibits IL-6\/STAT3 signaling to suppress triple-negative breast cancer xenografts in nude mice [in Chinese]","volume":"42","author":"Fang Y","year":"2022","unstructured":"Fang Y, Wang S, Yang Q, et al. Decoction plus or minus formula combined with capecitabine inhibits IL-6\/STAT3 signaling to suppress triple-negative breast cancer xenografts in nude mice [in Chinese]. Nan Fang Yi Ke Da Xue Xue Bao 2022; 42(6): 905\u2013912.","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"}],"container-title":["Journal of Investigative Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10815589241309603","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10815589241309603","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10815589241309603","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:40:18Z","timestamp":1777459218000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10815589241309603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,14]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1177\/10815589241309603"],"URL":"https:\/\/doi.org\/10.1177\/10815589241309603","relation":{},"ISSN":["1081-5589","1708-8267"],"issn-type":[{"value":"1081-5589","type":"print"},{"value":"1708-8267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,14]]}}}